BR112022023486A2 - Tratamento para amiloidose - Google Patents
Tratamento para amiloidoseInfo
- Publication number
- BR112022023486A2 BR112022023486A2 BR112022023486A BR112022023486A BR112022023486A2 BR 112022023486 A2 BR112022023486 A2 BR 112022023486A2 BR 112022023486 A BR112022023486 A BR 112022023486A BR 112022023486 A BR112022023486 A BR 112022023486A BR 112022023486 A2 BR112022023486 A2 BR 112022023486A2
- Authority
- BR
- Brazil
- Prior art keywords
- amyloidosis
- treatment
- formula
- compounds
- amylodosis
- Prior art date
Links
- 206010002022 amyloidosis Diseases 0.000 title abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010016202 Familial Amyloidosis Diseases 0.000 abstract 2
- 208000016463 Wild type ABeta2M amyloidosis Diseases 0.000 abstract 2
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 208000017105 hereditary amyloidosis Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063027194P | 2020-05-19 | 2020-05-19 | |
| PCT/US2021/032808 WO2021236543A1 (en) | 2020-05-19 | 2021-05-17 | Treatment for amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022023486A2 true BR112022023486A2 (pt) | 2023-01-10 |
Family
ID=78708017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022023486A BR112022023486A2 (pt) | 2020-05-19 | 2021-05-17 | Tratamento para amiloidose |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230210846A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4138837A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023527741A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230013102A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116133661A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021273731A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022023486A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183746A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298297A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014468A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202207931A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021236543A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024546584A (ja) * | 2021-12-15 | 2024-12-26 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Ｂｃｌ－２阻害剤、ｗｅｅ－１阻害剤及び他の化学療法剤の三剤療法の組み合わせ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL316472A (en) * | 2018-01-10 | 2024-12-01 | Recurium Ip Holdings Llc | Benzamide compounds |
| US20210154368A1 (en) * | 2018-04-09 | 2021-05-27 | Case Western Reserve University | Bioink and crosslinkable support medium for printing |
| US10659731B2 (en) * | 2018-04-10 | 2020-05-19 | Facebook, Inc. | Automated cinematic decisions based on descriptive models |
| US10526132B2 (en) * | 2018-04-10 | 2020-01-07 | Dow Global Technologies Llc | Dispenser for can with fixed valve stem housing |
-
2021
- 2021-05-17 CN CN202180060027.8A patent/CN116133661A/zh active Pending
- 2021-05-17 KR KR1020227044559A patent/KR20230013102A/ko not_active Withdrawn
- 2021-05-17 WO PCT/US2021/032808 patent/WO2021236543A1/en not_active Ceased
- 2021-05-17 EP EP21807581.0A patent/EP4138837A4/en active Pending
- 2021-05-17 CA CA3183746A patent/CA3183746A1/en active Pending
- 2021-05-17 BR BR112022023486A patent/BR112022023486A2/pt not_active Application Discontinuation
- 2021-05-17 AU AU2021273731A patent/AU2021273731A1/en not_active Abandoned
- 2021-05-17 IL IL298297A patent/IL298297A/en unknown
- 2021-05-17 JP JP2022570279A patent/JP2023527741A/ja active Pending
- 2021-05-17 US US17/998,920 patent/US20230210846A1/en not_active Abandoned
- 2021-05-17 MX MX2022014468A patent/MX2022014468A/es unknown
- 2021-05-19 TW TW110118106A patent/TW202207931A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021236543A1 (en) | 2021-11-25 |
| MX2022014468A (es) | 2023-02-09 |
| JP2023527741A (ja) | 2023-06-30 |
| IL298297A (en) | 2023-01-01 |
| US20230210846A1 (en) | 2023-07-06 |
| CN116133661A (zh) | 2023-05-16 |
| KR20230013102A (ko) | 2023-01-26 |
| AU2021273731A1 (en) | 2022-12-15 |
| TW202207931A (zh) | 2022-03-01 |
| EP4138837A4 (en) | 2024-05-22 |
| EP4138837A1 (en) | 2023-03-01 |
| CA3183746A1 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006846A (es) | Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias. | |
| GT200600432A (es) | Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la beta-secretasa | |
| BR112021022061A2 (pt) | Inibidores de kcnt1 e métodos de uso | |
| SA521430751B1 (ar) | Kcnt1 مثبطات وطرق استخدامها | |
| BR112023014973A2 (pt) | Derivados de urolitina e métodos de uso dos mesmos | |
| MX2024008551A (es) | Terapias de combinacion. | |
| CY1112706T1 (el) | Παραγωγα 4-βενζυλαμινο-1-καρβοξυακυλ-πιπεριδινης ως αναστολεις της cετρ, χρησιμοι για τη θεραπεια ασθενειων οπως η υπερλιπιδαιμια ή η αρτήριοσκληρωση | |
| BRPI0606690A2 (pt) | composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica | |
| MX2021014350A (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. | |
| BR112022019041A2 (pt) | Inibidores de kcnt1 e métodos de uso | |
| ECSP21080096A (es) | Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra | |
| BR112017013768A2 (pt) | composto de bipiridina, composição, seu uso e método para o controle de um artrópode nocivo". | |
| CY1114091T1 (el) | ΠΑΡΑΓΟΝΤΕΣ ΓΙΑ ΠΡΟΛΗΨΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΔΙΑΤΑΡΑΧΩΝ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΟΥΝ ΔΙΑΦΟΡΟΠΟΙΗΣΗ ΤΩΝ ΥΠΟΔΟΧΕΩΝ RyR | |
| BR112022020147A2 (pt) | Compostos para tratar a doença de huntington | |
| BR112018002074A2 (pt) | composição, processo para a proteção de um material orgânico, uso de um composto, e, composto. | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| BRPI0613861B8 (pt) | derivados de isoquinolona piperidinil-substituídos como inibidores de rho-cinase | |
| BR112022005627A2 (pt) | Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica e uso de um composto | |
| EA201591918A1 (ru) | Производные тамоксифена для лечения новообразований, особенно с высоким уровнем белка her2 | |
| BR112022012280A2 (pt) | Combinações | |
| BR112022012281A2 (pt) | Combinações | |
| BR0207645A (pt) | Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos | |
| EA202190011A1 (ru) | ПРОИЗВОДНЫЕ ТИОФЕНА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, ВЫЗВАННЫХ IgE | |
| EA202092815A1 (ru) | Новый стабилизатор длительного действия для резины и резиновая смесь для шин, содержащая указанный стабилизатор | |
| AR132992A1 (es) | Agonistas de trem2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |